Search

Weilun Lo

Supervisory Patent Examiner (ID: 18192, Phone: (571)272-4847 , Office: P/2179 )

Most Active Art Unit
3402
Art Unit(s)
3747, 3723, 3402, 3748, 2899, 3761, 2179
Total Applications
2327
Issued Applications
2049
Pending Applications
47
Abandoned Applications
231

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18844516 [patent_doc_number] => 20230406920 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-21 [patent_title] => ANTI-SIGLEC-8 ANTIBODY FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/032788 [patent_app_country] => US [patent_app_date] => 2021-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 33943 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032788 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/032788
ANTI-SIGLEC-8 ANTIBODY FORMULATIONS Oct 20, 2021 Pending
Array ( [id] => 17385636 [patent_doc_number] => 20220033488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => CANCER TREATMENT BY BLOCKING HOST-INDUCED IL-1 IN COMBINATION WITH RADIOTHERAPY [patent_app_type] => utility [patent_app_number] => 17/451332 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6447 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 190 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17451332 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/451332
Cancer treatment by blocking host-induced IL-1 in combination with radiotherapy Oct 18, 2021 Issued
Array ( [id] => 18809015 [patent_doc_number] => 20230383350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => METHOD FOR PREDICTING THE RESPONSE TO TNF INHIBITORS [patent_app_type] => utility [patent_app_number] => 18/249756 [patent_app_country] => US [patent_app_date] => 2021-10-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15103 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18249756 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/249756
METHOD FOR PREDICTING THE RESPONSE TO TNF INHIBITORS Oct 18, 2021 Pending
Array ( [id] => 17520523 [patent_doc_number] => 20220106372 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-04-07 [patent_title] => METHODS, COMPOSITIONS AND USES THEREOF FOR REVERSING SACROPENIA [patent_app_type] => utility [patent_app_number] => 17/504158 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18077 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504158 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/504158
Methods, compositions and uses thereof for reversing sarcopenia Oct 17, 2021 Issued
Array ( [id] => 19121037 [patent_doc_number] => 11965007 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-04-23 [patent_title] => IL-15-based fusions to IL-7 and IL-21 [patent_app_type] => utility [patent_app_number] => 17/504100 [patent_app_country] => US [patent_app_date] => 2021-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 87 [patent_no_of_words] => 34731 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17504100 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/504100
IL-15-based fusions to IL-7 and IL-21 Oct 17, 2021 Issued
Array ( [id] => 18861891 [patent_doc_number] => 20230416326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-28 [patent_title] => MODIFIED INTERLEUKIN-2 (IL-2) MOLECULE AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/029673 [patent_app_country] => US [patent_app_date] => 2021-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -48 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18029673 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/029673
MODIFIED INTERLEUKIN-2 (IL-2) MOLECULE AND USE THEREOF Oct 15, 2021 Pending
Array ( [id] => 19709289 [patent_doc_number] => 20250019431 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-16 [patent_title] => KIDNEY TARGETED IMMUNOTOLERANCE [patent_app_type] => utility [patent_app_number] => 18/248398 [patent_app_country] => US [patent_app_date] => 2021-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 35147 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248398 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/248398
KIDNEY TARGETED IMMUNOTOLERANCE Oct 14, 2021 Pending
Array ( [id] => 18830887 [patent_doc_number] => 20230399412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-12-14 [patent_title] => ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO CD70, AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/248771 [patent_app_country] => US [patent_app_date] => 2021-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18248771 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/248771
ANTIBODY AND CHIMERIC ANTIGEN RECEPTOR (CAR) BINDING TO CD70, AND APPLICATION THEREOF Oct 11, 2021 Pending
Array ( [id] => 17482211 [patent_doc_number] => 20220089715 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-03-24 [patent_title] => METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY [patent_app_type] => utility [patent_app_number] => 17/494199 [patent_app_country] => US [patent_app_date] => 2021-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 119226 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17494199 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/494199
METHODS OF NEUTRALIZING IL-8 BIOLOGICAL ACTIVITY Oct 4, 2021 Pending
Array ( [id] => 17385620 [patent_doc_number] => 20220033472 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-03 [patent_title] => ANTI-VEGF PROTEIN COMPOSITIONS AND METHODS FOR PRODUCING THE SAME [patent_app_type] => utility [patent_app_number] => 17/492440 [patent_app_country] => US [patent_app_date] => 2021-10-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 53 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17492440 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/492440
Anti-VEGF protein compositions and methods for producing the same Sep 30, 2021 Issued
Array ( [id] => 20453057 [patent_doc_number] => 12516107 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-01-06 [patent_title] => Potent neutralizing antibodies for prevention and treatment of COVID-19 [patent_app_type] => utility [patent_app_number] => 18/028687 [patent_app_country] => US [patent_app_date] => 2021-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 15 [patent_no_of_words] => 8936 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18028687 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/028687
Potent neutralizing antibodies for prevention and treatment of COVID-19 Sep 28, 2021 Issued
Array ( [id] => 18171777 [patent_doc_number] => 11571470 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-02-07 [patent_title] => IL-15-based fusions to IL-12 and IL-18 [patent_app_type] => utility [patent_app_number] => 17/486683 [patent_app_country] => US [patent_app_date] => 2021-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 21 [patent_figures_cnt] => 32 [patent_no_of_words] => 29958 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17486683 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/486683
IL-15-based fusions to IL-12 and IL-18 Sep 26, 2021 Issued
Array ( [id] => 20178346 [patent_doc_number] => 20250262304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-08-21 [patent_title] => FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME [patent_app_type] => utility [patent_app_number] => 18/246656 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 101913 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246656 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/246656
FRATRICIDE RESISTANT MODIFIED IMMUNE CELLS AND METHODS OF USING THE SAME Sep 23, 2021 Pending
Array ( [id] => 18971914 [patent_doc_number] => 20240052006 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-02-15 [patent_title] => ANTI-INFLAMMATORY CYTOKINES AND METHODS OF USE [patent_app_type] => utility [patent_app_number] => 18/246512 [patent_app_country] => US [patent_app_date] => 2021-09-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37752 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18246512 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/246512
ANTI-INFLAMMATORY CYTOKINES AND METHODS OF USE Sep 23, 2021 Pending
Array ( [id] => 18672878 [patent_doc_number] => 20230310324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => METHOD OF MAKING LYOPHILIZED PROTEIN FORMULATIONS [patent_app_type] => utility [patent_app_number] => 18/024893 [patent_app_country] => US [patent_app_date] => 2021-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024893 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/024893
METHOD OF MAKING LYOPHILIZED PROTEIN FORMULATIONS Sep 13, 2021 Pending
Array ( [id] => 17704640 [patent_doc_number] => 20220204646 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-06-30 [patent_title] => Compositions and Methods of Use of Alpha-1 Antitrypsin Fusion Polypeptides [patent_app_type] => utility [patent_app_number] => 17/471466 [patent_app_country] => US [patent_app_date] => 2021-09-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17471466 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/471466
Compositions and methods of use of alpha-1 antitrypsin fusion polypeptides Sep 9, 2021 Issued
Array ( [id] => 19226714 [patent_doc_number] => 12006347 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-06-11 [patent_title] => Superagonists and antagonists of interleukin-2 [patent_app_type] => utility [patent_app_number] => 17/470246 [patent_app_country] => US [patent_app_date] => 2021-09-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 15718 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17470246 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/470246
Superagonists and antagonists of interleukin-2 Sep 8, 2021 Issued
Array ( [id] => 20240978 [patent_doc_number] => 12421286 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-09-23 [patent_title] => Il-2 mutant and application thereof [patent_app_type] => utility [patent_app_number] => 18/024151 [patent_app_country] => US [patent_app_date] => 2021-09-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 61 [patent_no_of_words] => 12375 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 150 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024151 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/024151
Il-2 mutant and application thereof Sep 2, 2021 Issued
Array ( [id] => 17299485 [patent_doc_number] => 20210395324 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-23 [patent_title] => MULTI-LEVEL SPECIFIC TARGETING OF CANCER CELLS [patent_app_type] => utility [patent_app_number] => 17/465145 [patent_app_country] => US [patent_app_date] => 2021-09-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13373 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17465145 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/465145
Multi-level specific targeting of cancer cells Sep 1, 2021 Issued
Array ( [id] => 18596032 [patent_doc_number] => 20230270823 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => LONG-ACTING IL-15 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/023702 [patent_app_country] => US [patent_app_date] => 2021-09-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22703 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18023702 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/023702
LONG-ACTING IL-15 AND USES THEREOF Aug 31, 2021 Pending
Menu